Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
44.75    2.25 (5.29%)
Bid:
44.50
Ask:
45.00
Spread: 0.50 (1.124%)
Market Cap: £85.86m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

Directorate Change

19 Sep 2013 07:00

RNS Number : 3675O
Iofina PLC
19 September 2013
 



19 September 2013

 

Iofina plc

("Iofina" or the "Group")

(LSE AIM: IOF)

CEO Appointment

 

Iofina, specialists in the exploration and production of iodine and iodine specialty chemical derivatives, is pleased to announce the appointment of George Everett Lantz, who will be joining the PLC Board as Chief Executive Officer with immediate effect. As previously stated, Dr. Chris Fay will return to his previous position of Non-Executive Chairman.

 

Mr Lantz (62) joins the Board with a demonstrable track record spanning over 30 years in industry. He was most recently a consultant to the Group division, Iofina Resources, Inc. During his time with Iofina Resources, Inc. Mr Lantz helped achieve a daily record iodine production. Mr Lantz was also responsible for financial controls, business development, and managed the build-out of the Group's IO#3, and the on-going construction of IO#4, IO#5, and IO#6, iodine extraction plants based on Iofina's WET® IOsorb™ technology.

 

Prior to joining Iofina Resources, Inc., Mr Lantz held the positions of Founder and Vice President at Voyant Technologies; Vice President at Polycom; Vice President of Frontier ConferTech; Corporate New Business Manager ROLM (a Siemens Company); Sales Engineer at IBM Corporation; and Design Engineer with Texaco, Inc. Mr Lantz has a Bachelor of Science in Civil Engineering and a Master of Science in Industrial Management from the University of Wyoming, USA. Mr Lantz owns 26,433 ordinary shares in Iofina, representing 0.02 per cent. of the issued share capital.

 

The enlarged Group Board now comprises four Non-Executive Directors and three Executive Directors.

 

Commenting on the appointment Dr. Chris Fay, Non-Executive Chairman said: We are delighted to welcome George to the Board at a very exciting time of becoming a preeminent fast growing iodine producer. George is extremely well prepared to head our experienced management team and drive the Group forward into its next stage of growth."

 

There is no further information required to be disclosed pursuant to paragraph (g) of Schedule 2 of the AIM Rules.

For further information, please contact:

 

George Lantz, CEO

Iofina plc

Tel: +44(0)20 3006 3135

www.iofina.com

 

Ben Colegrave/Chris Sim/ James Rudd

Investec

Tel: +44(0)20 7597 5970

 

Media Contact:

Dominic Barretto/Anna Legge

Yellow Jersey PR Limited

Tel: +44(0) 7768 537 739

 

About Iofina

 

Iofina specializes in the exploration and production of iodine, iodine specialty chemical derivatives, produced water and natural gas. Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America based on Iofina's WET® IOsorb™ technology. Iofina has iodine production operations in the United States, specifically in Texas, California, Montana, Oklahoma and Wyoming. The Group has complete vertical integration from the production of iodine in the field to the manufacture of the chemical end products derived from iodine to the consumer and the recycling of iodine using iodinated side-streams from waste chemical processes in Europe, North America and Asia. The Group utilizes its portfolio of patented and patent pending technology, proprietary methods and trademarks throughout all business lines.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGGUMABUPWGMR
Date   Source Headline
5th Jun 20267:00 amRNSAgreement Signed for Additional Brine Water Supply
5th May 20267:00 amRNSNotice of AGM
30th Apr 20264:45 pmRNSHolding(s) in Company
30th Apr 202611:30 amRNSHolding(s) in Company
30th Apr 20267:00 amRNSFinal Results
16th Apr 20261:40 pmRNSHolding(s) in Company
15th Apr 20267:00 amRNSQ1 2026 Corporate Update
20th Mar 202612:25 pmRNSHolding(s) in Company
13th Jan 20267:00 amRNSQ4 2025 Corporate Update
6th Jan 20267:00 amRNSHolding(s) in Company
12th Dec 20257:00 amRNSDirectorate change
5th Dec 20257:00 amRNSAgreement with Western Midstream
12th Nov 20258:15 amRNSHolding(s) in Company
16th Oct 20257:00 amRNSQ3 2025 Update
3rd Oct 20253:32 pmRNSHolding(s) in Company
18th Sep 20257:00 amRNSInterim Results
4th Sep 20257:00 amRNSBusiness Update
17th Jul 20257:00 amRNSH1 2025 Update
9th Jul 20257:00 amRNSCapital Reduction
9th Jun 20255:00 pmRNSResult of AGM
14th May 20257:00 amRNSNotice of AGM and Proposed Capital Reduction
12th May 20257:00 amRNS-RInvestor Presentation
12th May 20257:00 amRNSFinal Results
25th Apr 20253:45 pmRNSHolding(s) in Company
17th Apr 20257:00 amRNSQ1 2025 Update
23rd Jan 20257:00 amRNSQ4 2024 Update
18th Dec 20244:45 pmRNSHolding(s) in Company
21st Oct 20247:00 amRNSHolding(s) in Company
18th Oct 20247:00 amRNSQ3 2024 Update
27th Sep 20247:00 amRNSIO#11 Update
20th Sep 20247:00 amRNSInterim Results
13th Sep 20247:00 amRNSIO#10 Iodine Plant Commissioned
16th Jul 20247:00 amRNSH1 Update
27th Jun 202411:04 amRNSHolding(s) in Company
25th Jun 20247:00 amRNSHolding(s) in Company
13th Jun 20241:00 pmRNSResult of AGM
29th May 20244:50 pmRNSLaunch of new website
15th May 20247:00 amRNSNotice of AGM and Resignation of Director
2nd May 20247:00 amRNSFinal Results
16th Apr 20247:00 amRNSQ1 2024 Corporate Update
17th Jan 20247:00 amRNSHolding(s) in Company
15th Jan 20247:00 amRNSQ4 2023 Corporate Update
30th Nov 20237:00 amRNSIO#9 Update
20th Oct 20237:00 amRNSSigned Agreement for IO#10 and Q3 2023 Update
11th Sep 20237:00 amRNSInterim Results
25th Aug 20235:00 pmRNSHolding(s) in Company
24th Jul 20235:00 pmRNSHolding(s) in Company
20th Jul 20237:00 amRNSH1 Update and Updated Loan Facilities
14th Jun 20232:00 pmRNSResult of AGM
14th Jun 20237:00 amRNSIO#9 Iodine Plant Operating

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.